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Practice Patterns for Acute Ischemic Stroke Workup: A Longitudinal
Population-Based Study
Matthew C. Loftspring, MD, PhD; Brett M. Kissela, MD; Matthew L. Flaherty, MD; Jane C. Khoury, PhD; Kathleen Alwell, BSN;
Charles J. Moomaw, PhD; Dawn O. Kleindorfer, MD; Daniel Woo, MD; Opeolu Adeoye, MD; Simona Ferioli, MD; Joseph P. Broderick, MD;
Pooja Khatri, MD
Background-—We examined practice patterns of inpatient testing to identify stroke etiologies and treatable risk factors for acute
ischemic stroke recurrence.
Methods and Results-—We identiﬁed stroke cases and related diagnostic testing from four 1-year study periods (July 1993 to June
1994, 1999, 2005, and 2010) of the Greater Cincinnati/Northern Kentucky Stroke Study. Patients aged ≥18 years were included.
We focused on evaluation of extracranial arteries for carotid stenosis and assessment of atrial ﬁbrillation because randomized
controlled trials supported treatment of these conditions for stroke prevention across all 4 study periods. In each study period, we
also recorded stroke etiology, as determined by diagnostic testing and physician adjudication. An increasing proportion of stroke
patients received assessment of both extracranial arteries and the heart over time (50%, 58%, 74%, and 78% in the 1993–1994,
1999, 2005, and 2010 periods, respectively; P<0.0001 for trend), with the most dramatic individual increases in echocardiography
(57%, 63%, 77%, and 83%, respectively). Concurrently, we observed a decrease in strokes of unknown etiology (47%, 48%, 41%, and
38%, respectively; P<0.0001 for trend). We also found a signiﬁcant increase in strokes of other known causes (32%, 25%, 45% and
59%, respectively; P<0.0001 for trend).
Conclusions-—Stroke workup for treatable causes of stroke are being used more frequently over time, and this is associated with a
decrease in cryptogenic strokes. Future study of whether better determination of treatable stroke etiologies translates to a
decrease in stroke recurrence at the population level will be essential. ( J Am Heart Assoc. 2017;6:e005097. DOI: 10.1161/
JAHA.116.005097.)
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A s much as 25% of annual ischemic strokes are recurrentevents.1 Establishing stroke etiology is the cornerstone
to identifying treatable conditions that may reduce this risk.
Cryptogenic strokes occur at a yearly rate of at least 35%.2
Clearly, absence of the etiology of a stroke precludes any
targeted and thoughtful secondary prevention strategies;
therefore, cryptogenic strokes represent a barrier to reducing
stroke recurrence.
In the 1990s, with the publication of the NASCET (North
American Symptomatic Carotid Endarterectomy)3 and SPAF
(Stroke Prevention in Atrial Fibrillation)4 trials, treatment of
carotid stenosis ≥70% with carotid endarterectomy and
anticoagulation for nonvalvular atrial ﬁbrillation (AF) became
evidence-based interventions. Importantly, these interven-
tions were speciﬁcally targeted at a particular stroke
etiology. Consequently, assessment of the extracranial
arteries for high-grade stenosis and the heart for thrombi
or evidence of AF (eg, an enlarged left atrium) became
essential.5
In the current study, we hypothesized that more rigorous
use of appropriate investigative modalities to determine
stroke etiology would be associated with a decrease in
strokes of unknown etiology (cryptogenic strokes) over time.
Given that symptomatic carotid stenosis and AF are treatable
and that their treatment is known to improve outcomes, it is
essential to identify them during diagnostic testing.
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We reviewed stroke-related diagnostic testing for ﬁrst-ever
hospitalized ischemic strokes among residents of the Greater
Cincinnati/Northern Kentucky (GCNK) 5-county region of
1.3 million people during four 1-year study periods (July 1993
to June 1994 and calendar years 1999, 2005, and 2010). In
the region, 19 hospitals were active in 1993–1994, 18 in
1999, 17 in 2005, and 16 in 2010, including a broad range of
hospital types, ranging from small community hospitals to
large academic medical centers. This study was approved by
the institutional review boards of all participating hospitals for
each study period; given the observational nature of the study,
the requirement for informed consent was exempted.
Patients aged ≥18 years were included. The methods of the
GCNK Stroke Study have been reported previously.6 Brieﬂy, the
GCNK Stroke Study involved ascertainment of all stroke events
that occurred in the population during the 4 study periods. In
1993–1994, research nurses screened the medical records of
all inpatients with primary or secondary stroke-related Interna-
tional Classiﬁcation of Diseases, 9th Revision (ICD-9) discharge
diagnoses 430 to 438 from the acute care hospitals in the study
region. In 1999, 2005, and 2010, the ICD-9 codes 430 to 436
were used because of low yield from codes 437 and 438 in
1993–1994. In addition, strokes not found by inpatient screen-
ing were ascertained by monitoring all stroke-related visits to
hospital emergency departments, public health clinics, hospital-
based outpatient clinics, and family practice centers. Patients
for whom stroke was listed as the primary or secondary cause of
death by the county coroners’ ofﬁces were also included.
The seminal SPAF and NASCET studies, which supported
assessment of the heart and extracranial vessels, were
published by 1991. Therefore, we deﬁned a complete workup
as a combination of (1) echocardiography or history of AF
(which already suggests a cardioembolic source and may not
necessitate echocardiogram) and (2) evaluation of extracra-
nial arteries by carotid ultrasound, magnetic resonance
angiogram (MRA), or digital subtraction angiography. We
utilized a hierarchy of etiology to assign a “ﬁnal” cause of
stroke that gave highest priority to the most distal cause.
Speciﬁcally, we recorded testing aimed at determination of
the following stroke etiologies: (1) large vessel atherothrom-
bosis (by carotid ultrasound or MRA), with the goal of
determining those who would beneﬁt from carotid endarterec-
tomy or stenting; (2) cardioembolism (by ECG, echocardio-
gram, or history of AF). Notably, we did not include patent
foramen ovale as cardioembolic unless a peripheral source
was found such as a deep vein thrombosis; (3) small vessel
atherosclerosis (by computed tomography or magnetic reso-
nance imaging [MRI]). We requested ﬁlms and measured
infarcts when relevant for diagnosing a small vessel etiology
which required infarcts of <1.5 cm in diameter, and size was
not available in the radiological report. Of note, computed
tomography angiogram was performed infrequently in the
early study periods, and we did not abstract data on whether
those studies included head, neck, or both; therefore, this
information was not included in the temporal trends table.
Similarly, we did not abstract data on prolonged outpatient
cardiac rhythm monitoring until the most recent study period.
Statistics
The data weremanaged and analyzedwith SAS version 9.3 (SAS
Institute, Cary, NC). Only ﬁrst-ever ischemic stroke cases
evaluated in an emergency department were used for this
analysis. The same clinical deﬁnition of ischemic stroke was
used in each time period (ie, acute onset of focal neurological
signs consistent with a cerebrovascular lesion and a negative
noncontrast head computed tomography for intracranial hem-
orrhage). Analysis of the demographic variables involved
assessment of change over time. For the continuous variables
age and systolic blood pressure, year was treated as an interval
variable (4 time points) in the general linear model. For National
Institutes of Health Stroke Scale (NIHSS) score, there were only
2 time points, and due to the distribution of the score, a
Wilcoxon rank sum test was used to examine the difference
between 2005 and 2010. For the remaining categorical
variables, the Cochran-Armitage test for trend was used, with
P<0.05 considered statistically signiﬁcant; this 2-tailed P value
was calculated from the Z distribution. For examination of the
stroke etiology, a Bonferroni correction was used for evaluation
of the critical value for the outcome variables.
Results
The baseline patient characteristics are shown in Table 1. The
numbers of patients were 1458, 1455, 1403, and 1475 in
Clinical Perspective
What Is New?
• The inpatient evaluation of acute ischemic stroke has
changed over time in our population.
• From 1993 to 2010, there has been an increase in
diagnostic modalities aimed at assessing extracranial
carotid disease, cardioembolism, and small vessel disease.
• Concurrently, we observed a decrease in the frequency of
cryptogenic stroke (from 47% to 38%).
What Are the Clinical Implications?
• More frequent identiﬁcation of stroke etiology is essential
for discovery and successful implementation of secondary
prevention strategies.
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1993–1994, 1999, 2005, and 2010, respectively. Across the
study periods, there was a decrease in mean age (72.4 years
in 1993–1994 versus 69.0 years in 2010; P<0.001), an
increase in the proportion of black participants (17.6% versus
20.3%; P=0.006), and a small decrease in baseline systolic
blood pressure (164.3 versus 158.3 mm Hg; P<0.0001).
There were increases in the proportion of patients with
coronary artery disease (17.2% versus 31.1%), hypertension
(60.0% versus 79.0%), and current smoking (21.5% versus
28.3%; P<0.0001 for each trend). In 2005 and 2010,
respectively, 5% and 6% of patients had NIHSS >20.
Across the 4 study periods, we observed a signiﬁcant
increase in stroke patients that had both cardiac and
extracranial artery assessments (ie, our deﬁnition of a
complete workup); in 2010, 78% of patients had complete
assessments compared with 74% in 2005, 58% in 1999, and
50% in 1993–1994 (Table 2). The largest increase was seen in
cardiac assessment with echocardiography, from 57% in
1993–1994 to 83% in 2010. Unfortunately, we did not have
data regarding prolonged cardiac rhythm monitoring in the
earlier study periods, given that this modality is relatively new.
We also performed MRIs and MRAs more frequently (18% and
8%, respectively) in 1993–1994 compared with 2010 (74%
and 47%, respectively). Moreover, there was an increase in
the assessment of lipids, as shown by either a history of
hyperlipidemia or testing of lipids during hospitalization (from
51% in 1993–1994 to 86% in 2010, P<0.0001 for trend). Even
in the 2 most recent study periods (2005 and 2010), there
continued to be an increasing proportion of patients who
received a complete workup (Table S1).
Across study periods, the number of strokes classiﬁed as
undetermined was reduced from 46% in 1993–1994 to 38% in
2010 (P<0.0001 for trend; Table 3). In the 2 most recent
study periods, there was a smaller proportion of
undetermined strokes from 2005 to 2010; however, this
difference did not reach statistical signiﬁcance (Table S2).
Discussion
In our study, there was an increase over time in diagnostic tests
aimed at identiﬁcation of strokes attributable to large vessel
disease (primarily through the increased use of MRA), car-
dioembolism (through more frequent echocardiograms), and
small vessel disease (through more rigorous brain imaging and
assessment of lipids). Concurrently, we observed a decrease in
the frequency of cryptogenic stroke (from 47% to 38%).
Although there was an increase in the frequency of MRAs,
we did not ﬁnd a change in the number of large vessel
strokes. An explanation is that MRAs were being done for
reasons other than assessment of extracranial carotid
stenosis. In these cases, there would have been a low pretest
suspicion of signiﬁcant carotid disease. With the increase in
MRIs, we identiﬁed more strokes caused by small vessel
disease. This increase in small vessel disease may also be
related to having more evidence that strokes were not due to
large vessel disease because there was also an increase in
cardiac assessment and more frequent identiﬁcation of
cardioembolic strokes over time. The sharp increase in the
proportion of patients with a diagnosis of hyperlipidemia most
likely reﬂects better understanding of cardiovascular event
risk factors or more frequent diagnosis, as opposed to a
signiﬁcant increase in the true prevalence. Alternatively, there
may have been increased adherence to clinical quality
measures. Indeed, the ﬁrst major randomized controlled trial
for cholesterol reduction in secondary stroke prevention was
SPARCL, published in 2006. SPARCL demonstrated a 5-year
absolute risk reduction of 2.2% in participants treated with
80 mg of atorvastatin, with even greater beneﬁt in the
Table 1. Patient Demographics by Study Period
1993–1994 (n=1458) 1999 (n=1455) 2005 (n=1403) 2010 (n=1475) P Value (for Time Trend)
Age, meanSD 72.412.7 72.113.6 69.115.1 69.015.3 <0.001
Female, n (%) 826 (56.6) 806 (55.4) 780 (55.6) 820 (55.6) 0.60
Black, n (%) 256 (17.6) 257 (17.7) 305 (21.7) 300 (20.3) 0.006
Baseline NIHSS, median Not recorded Not recorded 3 (2–7) 3 (1–6) <0.0001
Baseline SBP, meanSD 164.350.9 164.046.2 158.431.9 158.331.1 <0.0001
CAD, n (%) 250 (17.2) 456 (31.3) 403 (28.7) 459 (31.1) <0.0001
CHF, n (%) 241 (16.5) 233 (16.0) 218 (15.5) 253 (17.2) 0.78
Hypertension, n (%) 875 (60.0) 977 (67.2) 1052 (75.0) 1166 (79.0) <0.0001
Current smoker, n (%) 313 (21.5) 331 (22.8) 359 (25.6) 418 (28.3) <0.0001
Prior TIA, n (%) 193 (13.2) 152 (10.4) 211 (15.0) 197 (13.4) 0.20
CAD indicates coronary artery disease; CHF, congestive heart failure; NIHSS, National Institutes of Health Stroke Scale; SBP, systolic blood pressure; TIA, transient ischemic attack.
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subgroup with low-density lipoprotein <70 mg/dL.7 We also
observed an increase in the use of statins over our study
periods that may be related to the increased diagnosis of
hyperlipidemia.
It is important to mention several limitations of the current
study. First, our study represents a Midwestern population of
1.3 million. It is unclear whether our practice patterns, patient
demographics, and health care system characteristics are
generalizable to other regions, although we know, based on
census data, that our region is representative of the United
States with regard to median age, percentage of black
persons, median household income, and percentage of the
population below the poverty level (Table 4). Second, with
respect to detection of paroxysmal AF, it is known that
transthoracic echocardiogram and a single ECG are not
sensitive.8 A limitation of our study is that we did not have
data on the frequency of telemetry use on the inpatient stroke
unit for all study periods or on discharge with Holter or 30-day
event monitors. Transthoracic echocardiogram use, however,
would evaluate for focal wall motion abnormalities, intracar-
diac shunts, thrombi, or valvular abnormalities, all of which
could lead to cardioembolism. Third, the median NIHSS score
from the 2005 and 2010 study periods was 3, indicating that
the majority of strokes were mild. It is possible that more
testing is done for mild strokes because their etiologies are
less apparent and because the patients may be eligible for
more risk-reduction treatments such as anticoagulation and
carotid endarterectomy. Unfortunately, we do not have
Table 2. In-Hospital Ischemic Stroke Workup by Study Period
Diagnostic Test 1993–1994 (n=1458) 1999 (n=1455) 2005 (n=1403) 2010 (n=1475) P for Time Trend
Standard tests, n (%)
Complete workup* 722 (50) 837 (58) 1036 (74) 1144 (78) <0.0001
Cardiac assessment 917 (63) 1007 (69) 1140 (81) 1293 (88) <0.0001
ECG 1329 (91) 1358 (93) 1344 (96) 1451 (98)
Telemetry Not recorded Not recorded Not recorded 1342 (91)
History of AF 218 (15) 211 (14) 204 (15) 323 (22)
Echocardiogram 837 (57) 917 (63) 1085 (77) 1224 (83)
Extracranial arteries assessed† 982 (67) 1065 (73) 1185 (84) 1252 (85) <0.0001
Carotid ultrasound 926 (64) 924 (64) 830 (59) 900 (61)
MRA 118 (8) 224 (15) 684 (49) 698 (47)
Digital subtraction angiogram 61 (4) 70 (5) 45 (3) 35 (2)
Carotid ultrasound and MRA 82 (6) 108 (7) 339 (24) 355 (24)
Carotid ultrasound only 809 (55) 787 (54) 482 (34) 543 (37)
MRA only 36 (2) 107 (7) 330 (24) 328 (22)
Brain imaging 1378 (94.5) 1444 (99.2) 1401 (99.9) 1474 (99.9) <0.0001
CT of head 1365 (94) 1427 (98) 1378 (98) 1441 (98)
MRI of brain 259 (18) 441 (30) 932 (66) 1096 (74)
Risk factor screening, n (%)
Lipids assessed 749 (51) 594 (41) 982 (70) 1264 (86) <0.0001
History of hyperlipidemia 131 (9) 294 (20) 498 (36) 737 (50)
Lipid levels 702 (48) 384 (26) 759 (54) 1024 (69)
Statin on admission 37 (3) 197 (14) 390 (28) 528 (36) <0.0001
Statin on discharge Not recorded Not recorded 605 (43) 850 (58) <0.0001
Diabetes mellitus assessed Not recorded Not recorded 993 (71) 1275 (86) <0.0001
History of diabetes mellitus 398 (27) 437 (30) 441 (31) 484 (33)
Hemoglobin A1c Not recorded Not recorded 269 (19) 526 (36)
Fasting glucose Not recorded Not recorded 741 (53) 1177 (80)
AF indicates atrial ﬁbrillation; CT, computed tomography; MRA, magnetic resonance angiogram; MRI, magnetic resonance imaging.
*Complete workup was considered to be assessment of extracranial carotids and history of atrial ﬁbrillation or echocardiography.
†Deﬁned as having at least 1 of the following: carotid ultrasound, MRA, or digital subtraction angiogram.
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information about the median NIHSS scores from the 2 earlier
time points to formally consider whether milder strokes are
associated with an increase in testing. It should also be noted
that we might have underestimated the frequency of essential
diagnostic testing. Some tests may have occurred in an
outpatient setting, and others may have had appropriately
limited workup because of terminal stroke or comorbidities
that limit subsequent secondary prevention therapies (eg,
anticoagulation or carotid endarterectomy). Nevertheless,
given that only 5% and 6% of patients had NIHSS >20 in
2005 and 2010, respectively, it is unlikely that a signiﬁcant
number of patients had testing limited because of terminal
strokes. Similarly, we do not have information regarding
initiation or adherence to risk-reduction treatments; therefore,
we do not have sufﬁcient data to make any direct associations.
Annual recurrent stroke rates seen in clinical trials have
decreased over the past 50 years by 3.5%.9 A recent meta-
analysis found that increasing use of antiplatelet drugs and
antihypertensive medications was associated with this
decline,8 although a causal relationship clearly cannot be
determined. It may also be speculated that carotid
endarterectomy and anticoagulation have reduced recurrent
strokes in patients with high-grade carotid stenosis and AF,
respectively. Furthermore, because there was more rigorous
testing, there were fewer cryptogenic strokes in the current
study. Because our deﬁnition of complete workup included a
known history of certain stroke risk factors, this change could
be due to better premorbid medical care.
Three main criteria have historically been used in assigning
the cause of stroke as cryptogenic.10 First are cases in which
no apparent cause can be determined despite an appropriate
evaluation. Second are others that may have no obvious
etiology, but the workup was not thorough. Finally, some
patients have ≥2 likely causes; therefore, 1 etiology cannot be
assigned. In our study, we assigned the ﬁnal cause as the most
distal. A patient with AF and ipsilateral carotid stenosis, for
example, would be labeled as carotid stenosis. Nonetheless, we
found that 38% of strokes still had no identiﬁable etiology
despite appropriate workup; others have reported similar
numbers.2 Of note, MRIs were not obtained for all patients to
assist in determining etiology, perhaps because MRI is not well
established to change outcome. At the least, these ﬁndings
underscore the need to maximize investigations that lead to
evidence-based stroke risk reduction. In the future, it will be
important to determine whether rigorous workups translate
into reduction of recurrent strokes at the population level.
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Table 3. Etiology Determined by Diagnostic Testing and Physician Adjudication
Etiology 1993–1994 (n=1458) 1999 (n=1455) 2005 (n=1403) 2010 (n=1475) P Value*
Small vessel 240 (17) 216 (15) 278 (20) 264 (18) 0.04
Cardioembolic 321 (22) 301 (21) 300 (21) 404 (27) 0.0006
Large vessel 187 (13) 209 (14) 199 (14) 186 (13) 0.82
Other known cause (all) 32 (2.2) 25 (1.7) 45 (3.2) 59 (4.0) 0.0003
Other known cause (not iatrogenic) 20 (2.2) 21 (1.7) 41 (3.2) 55 (4.0) <0.0001
Iatrogenic/periprocedural 12 (0.82) 4 (0.27) 4 (0.29) 4 (0.27) 0.09
Dissections 2 (0.14) 7 (0.48) 16 (1.14) 18 (1.22) 0.0004
Undetermined 678 (47) 704 (48) 581 (41) 562 (38) <0.0001
Data are shown as n (%).
*Only those signiﬁcant at the 0.01 level are considered statistically signiﬁcant (Bonferroni correction).
Table 4. GCNK Vs US Population (2010 Census)
Demographic GCNK United States
Size 1 368 604 308 700 000
Median age, y 34 37
Black, % 16.3 13.1
White, % 79.8 78.1
Median household income $53 178 $52 762
Below poverty, % 13.5 14.3
High school graduate, % 87.9 85.4
GCNK indicates Greater Cincinnati/Northern Kentucky.
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Complete Workup 1036 (74%) 1144 (78%) 0.02 
Cardiac Assessment 1140 (81%) 1293 (88%) <0.0001 
Extracranial Arteries Assessed 1185 (84%) 1252 (85%) 0.75 
 






Table S2. Etiology Determined by Diagnostic Testing and Physician Adjudication, 2005 and 
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